For many people who have experienced diabetic macular edema (DME), the future looks a little clearer. On August 10, 2012, the U.S. Food and Drug Administration (FDA) approved use of the drug Lucentis for the treatment of DME. Developed by Genentech, Lucentis is the first and only FDA-approved medicine for the condition. Diabetic macular edema […]
The collaborative partnership of JDRF and The Leona M. and Harry B. Helmsley Charitable Trust has awarded a new grant in one of the most exciting and promising areas of type 1 diabetes (T1D) research. The $4.6-million grant, distributed over three years, will fund the beta cell encapsulation research of Camillo Ricordi, M.D., scientific director […]
Developing effective treatments for diabetic retinopathy is a key part of JDRF’s research goals. Until recently, the only treatment for diabetic macular edema was with lasers that often halted the worsening of the condition but did not improve a person’s eyesight. Now, however, a promising new treatment has emerged in the form of a drug called Lucentis (known generically as ranibizumab).
Researchers at the University of Alberta have reported that a two-drug combination, sitagliptin and pantoprazole, can restore insulin independence in some islet transplant recipients with early signs of transplant failure. The effect was not sustained after withdrawal of the drugs; there was lack of evidence for durable effects on beta cell function or increased beta cell mass. JDRF continues to support research to improve long-term islet transplant function and to promote beta cell regeneration in all people with T1D.
In the JDRF-funded Medalist Study of individuals who have lived with T1D for at least 50 years, researchers have discovered that some Medalists are protected from advanced diabetic retinopathy because they have a slow rate of retinopathy onset or progression. Further, after 20 years of T1D, progression of retinopathy appears to halt. Researchers can now search for factors that mediate this slow disease progression and exploit them to develop new strategies to prevent or treat diabetic retinopathy.
A first-of-its-kind clinical pilot study has demonstrated the safety and feasibility of an artificial pancreas system in an outpatient, “real-world” setting. A second clinical study has shown that a hypoglycemia-hyperglycemia minimizer system can predict when blood-glucose levels are about to rise or fall and make appropriate adjustments in insulin delivery. These JDRF-supported studies represent critical steps on the path to a functional artificial pancreas for the benefit of people living with T1D.
On May 27, JDRF was featured in AMC’s new original series called The Pitch, an unscripted show that goes behind the scenes at two advertising agencies competing against each other to win the business of a high-profile client. The episode showed two agencies—Bozell and Muse—vying to best represent JDRF’s goal to improve the lives of all […]
Question: I recently married and moved to a new area. I found a physician for type 1 diabetes (T1D) care and checked his credentials, and he seems good “on paper.” But is there a checklist of questions I can ask to gauge whether this is the right physician for me? Answer: First, congratulations on this […]